2015 Volume 74 Issue 5 Pages 219-221
Autologous peripheral blood stem cell transplantation for multiple myeloma and the impact novel therapies after APBSCT improve survival. But upper limit of age who indicate APBSCT is under 65-year-old. Recently, tandem stem cell transplantation such as auto-allo, or double APBSCT are more improves outcome of patient with high risk. Also bortezomib and immunomodulatory drugs are powerful tool after transplantation maintenance therapy.